Ipratropium: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ipratropium. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Bronchitis | 24.5% |
| Dyspnea | 16.7% |
| Upper respiratory tract infection | 16% |
| Headache | 9% |
| Tremor | 8.3% |
| Coughing | 8% |
| Influenza-like symptoms | 6.5% |
| Nervousness | 6.5% |
| Respiratory disorder | 6.5% |
| Chest pain | 5.6% |
| Pharyngitis | 5.6% |
| Bronchospasm | 5.4% |
| Sinusitus | 5.4% |
| Pain | 5% |
| Insomnia | 4.6% |
| Sputum increased | 4.6% |
| Rhinitis | 4.2% |
| Nausea | 4.1% |
| Hypertension/hypertension aggravated | 4% |
| Dizziness | 4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Source: FDA labeling via NIH DailyMed (set 7159cf05…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.